All 99 /Abstracts 18 /Events 10 /In The News 7 /Press Releases 57 /Publications 23

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients…
28 April 2020/by circlek

Karus Therapeutics Announces New Data from Phase I Cancer Trial at AACR

Oxfordshire, UK, 27 April 2020 – Karus Therapeutics Ltd (‘Karus’),…
27 April 2020/by circlek

ASH Annual Meeting & Exposition

7-10 December 2019
ASH Annual Meeting & Exposition
Orlando,…
10 December 2019/by circlek

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma

Results of a First in Human, Dose Ascending, Phase I Study Examining…
10 December 2019/by circlek

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH

Oxfordshire, UK, 4 December 2019 – Karus Therapeutics Ltd (‘Karus’),…
4 December 2019/by circlek

Karus Therapeutics features in Biology Impacting Lives programme

Oxfordshire, UK, 11 October 2019 – Karus Therapeutics, a clinical-stage…
11 October 2019/by circlek

Karus Therapeutics Appoints Dr Stephen Shuttleworth as Chairman of Scientific Advisory Board

ANNOUNCEMENT

Oxfordshire, UK, 17 September 2019 – Karus…
17 September 2019/by circlek

Karus Therapeutics Strengthens Clinical Leadership Team with Appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer

Oxfordshire, UK, 17 July 2019 – Karus Therapeutics Ltd (‘Karus’),…
17 July 2019/by circlek

FASEB Ion Channel Regulation Conference: Molecules to Disease

7-12 July 2019
FASEB Ion Channel Regulation Conference: Molecules…
12 July 2019/by circlek

15-ICML International Conference on Malignant Lymphoma

18-22 June 2019
15-ICML International Conference on Malignant…
22 June 2019/by circlek

2018 Operational Update

Tim Edwards appointed as Executive Chairman
KA2237 and KA2507…
31 December 2018/by circlek

Genesis 2018

13 December 2018
Genesis 2018
London, UK
13 December 2018/by circlek

30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

13-16 November 2018
30th EORTC-NCI-AACR Symposium on Molecular…
16 November 2018/by circlek

BIO-Europe

5-7 November 2018
BIO-Europe
Copenhagen, Denmark & Malmö,…
7 November 2018/by circlek

NCRI Cancer Conference

4-6 November 2018
NCRI Cancer Conference
Glasgow, UK
6 November 2018/by circlek

BIA UK Bioscience Forum

18 October 2018
BIA UK Bioscience Forum
London, UK
18 October 2018/by circlek

ELRIG Drug Discovery 2018

9-10 October 2018
ELRIG Drug Discovery 2018
London, UK
10 October 2018/by circlek

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells…
8 June 2018/by circlek

Inhibition of histone deacetylase 6 reveals a potent immunosuppressant effect in models of transplantation.

Inhibition of histone deacetylase 6 reveals a potent immunosuppressant…
1 June 2018/by circlek

AACR Annual Meeting 2018

14-18 April 2018
AACR Annual Meeting 2018
Chicago, USA
Stephen…
18 April 2018/by circlek

Functional characterization of a novel somatic mutation of PIK3CB

Functional characterization of a novel somatic mutation of PIK3CB
Whale…
20 November 2017/by circlek

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

Oxfordshire, UK, 18th September 2017 – Karus Therapeutics…
18 September 2017/by circlek

Karus Therapeutics presenting at the CHI DoT 11th Annual Next-Generation Histone Deacetylase Inhibitors conference

Oxford, UK, 4 August 2017 – Karus Therapeutics Ltd, a leader…
4 August 2017/by circlek

Karus Therapeutics presenting at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design

Oxford, UK, 1 May 2017 – Karus Therapeutics Ltd, a leader in…
1 May 2017/by circlek

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell…
1 April 2017/by circlek

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237…
3 December 2016/by circlek

Karus Therapeutics features in BioCentury Innovations

Oxford, UK, 4 November 2016 – Karus Therapeutics, a leader…
4 November 2016/by circlek

Karus Therapeutics presenting at BIO-Europe

Oxford, UK, 21 October 2016 – Karus Therapeutics Ltd, a leader…
21 October 2016/by circlek

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

First cohort of cancer patients has been dosed with Karus’s…
5 October 2016/by circlek

Karus Therapeutics giving lecture at BIO Investor

Oxford, UK, 3 October 2016 – Karus Therapeutics Ltd, a leader…
3 October 2016/by circlek

Karus Therapeutics giving lecture at 10th Annual Symposium – Next Generation Histone Deacetylase Inhibitors

Oxford, UK, 7 September 2016 – Karus Therapeutics, a leader…
7 September 2016/by circlek

Karus Therapeutics delivering lecture at 9th Annual Kinase Inhibitor Discovery conference

Oxford, UK, 1 September 2016 – Karus Therapeutics, a leader…
1 September 2016/by circlek

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (Mainz)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting…
10 May 2016/by circlek

Karus Therapeutics presenting at BioEquity 2016

Oxford, UK, 21 April 2016 - Karus Therapeutics, a leader in the…
21 April 2016/by circlek

KA2237 and KA2507. Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (New Orleans)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting…
16 April 2016/by circlek

Karus Therapeutics presenting at AACR Annual Meeting 2016

Oxford, UK, 29 March 2016– Karus Therapeutics, a leader in…
29 March 2016/by circlek

Karus Therapeutics presenting at BioTrinity 2016

Oxford, UK, 21 March 2016 – Karus Therapeutics, a leader in…
21 March 2016/by circlek

Karus Therapeutics presenting at Sachs 9th Annual European Life Science CEO Forum & Exhibition

Oxford, UK, 1 March 2016 – Karus Therapeutics, a leader in…
1 March 2016/by circlek

Karus Therapeutics Announces Strategic Collaboration with The University of Texas MD Anderson Cancer Center

Oxford, UK, 10 December 2015 – Karus Therapeutics (‘Karus’),…
10 December 2015/by circlek

Karus Therapeutics presenting at the 4th Annual Cancer BioPartnering & Investment Forum

Oxford, UK, 7 December 2015 – Karus Therapeutics, a leader…
7 December 2015/by circlek

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Orlando)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237…
5 December 2015/by circlek

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Brussels)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237…
4 December 2015/by circlek

Karus Therapeutics presenting at the 8th Annual Biotech Showcase 2016

Oxford, UK, 30th November 2015 – Karus Therapeutics, a leader…
30 November 2015/by circlek

Karus Therapeutics presenting at the 57th ASH Annual Meeting

Oxford, UK, 26th November 2015 – Karus Therapeutics, a leader…
26 November 2015/by circlek

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Boston)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237…
7 November 2015/by circlek

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (Boston)

Design and Development of a Novel HDAC6-Selective Inhibitor,…
6 November 2015/by circlek

Karus Therapeutics presenting at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development

Oxford, UK, 2 November 2015 – Karus Therapeutics, a leader…
2 November 2015/by circlek

Karus Therapeutics presenting AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oxford, UK, 4 October 2015 – Karus Therapeutics, a leader in…
4 October 2015/by circlek

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (New York)

Design and Development of a Novel HDAC6-Selective Inhibitor,…
18 September 2015/by circlek

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (New York)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237…
18 September 2015/by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers

Design and Development of a Novel Series of Orally-Active, Selective…
18 April 2015/by circlek

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Hematological and Solid Tumors

Design and Development of a Novel Series of HDAC6-Selective Inhibitors…
18 April 2015/by circlek

Karus Therapeutics presenting at Sachs Immuno-oncology: BD&L and Investment Forum

Karus Therapeutics, a leader in the development of innovative…
15 April 2015/by circlek

Karus Therapeutics presenting at BioTrinity 2015

Simon Kerry, CEO of Karus Therapeutics, a leader in the development…
18 March 2015/by circlek

Karus Therapeutics presenting at AACR Annual Meeting 2015

Karus Therapeutics, a leader in the development of innovative…
18 March 2015/by circlek

Karus Therapeutics presenting at Biotech Showcase 2015

Dr Simon Kerry, CEO of Karus Therapeutics, a leader in the development…
19 December 2014/by circlek

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors…
3 November 2014/by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (NCRI Meeting)

Design and Development of a Novel Series of Orally-Active, Selective…
3 November 2014/by circlek

Karus Therapeutics Appoints New Head of Clinical Development and Head of Biology

Oxford, UK, 21 October 2014 – Karus Therapeutics, a leader…
21 October 2014/by circlek

Karus Therapeutics presenting at NCRI Cancer Conference

Stephen Shuttleworth, CSO of Karus Therapeutics, a leader in…
29 September 2014/by circlek

Karus Therapeutics presenting at SACHS Biotech in Europe Forum

Karus Therapeutics, a leader in the development of innovative…
8 September 2014/by circlek

Karus Therapeutics features in SciBX

Oxford, UK, 15 May 2014 – Karus Therapeutics, a leader in the…
15 May 2014/by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (San Diego)

Design and Development of a Novel Series of Orally-Active, Selective…
5 April 2014/by circlek

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer

Design and Development of a Novel Series of HDAC6-Selective Inhibitors…
5 April 2014/by circlek

Karus Therapeutics presenting at AACR Annual Meeting 2014

Oxford, UK, 3 April 2014 – Karus Therapeutics, a leader in…
3 April 2014/by circlek

Karus Therapeutics showcased in BVCA’s Britain’s Hot Talents 2014/15

Oxford, UK, February 2014 – Karus Therapeutics, a leader in…
25 February 2014/by circlek

Karus Therapeutics Appoints Penelope Ward as CMO

Oxford, UK, 12 November 2013 – Karus Therapeutics, a leader…
12 November 2013/by circlek

Karus Therapeutics wins ‘Best Biotech Fundraiser’ award

Oxford, UK, 2 October 2013 – Karus Therapeutics, a leader in…
2 October 2013/by circlek

Karus Therapeutics shortlisted for key industry award

Oxford, UK, 26 September 2013 – Karus Therapeutics, a leader…
26 September 2013/by circlek

Karus Therapeutics secures prominent role in epigenetics debate at SciBX Summit 2013

Oxford, UK, 21 August 2013 – Karus Therapeutics, a leader in…
21 August 2013/by circlek

Karus Therapeutics interviewed by Pharma Television

Oxford, UK, 17 July 2013 – Karus Therapeutics, a leader in…
17 July 2013/by circlek

Karus Therapeutics features on BBC South News

Oxford, UK, 15 May 2013 – Karus Therapeutics, a leader in the…
15 May 2013/by circlek

Karus Therapeutics presenting at BIO, BioTrinity, Anglo-Nordic Biotech and Next-Gen Kinase Inhibitors

Oxford, UK, 19 April 2013 – Karus Therapeutics, a leader in…
19 April 2013/by circlek

Karus Therapeutics appoints Scientific Advisory Board and announces move to new Oxford facilities

Oxford, UK, 9 April 2013 – Karus Therapeutics, a leader in…
9 April 2013/by circlek

Collaboration with Babraham Institute to explore PI3 kinase inhibitors in the treatment of inflammatory diseases

Southampton, UK, 17 December 2012 – Karus Therapeutics, a leader…
17 December 2012/by circlek

Karus Therapeutics secures Series B financing from a syndicate of leading VC investors

Southampton, UK, 6 September 2012 – Karus Therapeutics, a leader…
6 September 2012/by circlek

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Progress in the preclinical discovery and clinical development…
1 January 2011/by circlek

Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.

Progress in the development of small molecule therapeutics targeting…
1 January 2011/by circlek

Karus Therapeutics secures further financing

Southampton, UK - 4 May 2010 - Innovative pharmaceutical company…
4 May 2010/by circlek

Karus develops new family of HDAC-6 selective inhibitors

Chilworth, UK - 18 February 2010 - Karus Therapeutics Ltd, a…
18 February 2010/by circlek

Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases.

Histone Deacetylase inhibitors: new promise in the treatment…
1 January 2010/by circlek

Karus Therapeutics and Queen Mary, University of London announce PI3 kinase collaboration

Chilworth, UK - 23 September 2009 - Karus Therapeutics Ltd, a…
23 September 2009/by circlek

Karus CSO to present at three industry conferences

Chilworth, UK - 17 August 2009 - Innovative pharmaceutical company…
17 August 2009/by circlek

Organ transplant rejection collaboration with University Hospital Birmingham

Chilworth, UK - 1 June 2009 - Innovative pharmaceutical company…
1 June 2009/by circlek

KTP award with King’s College

Chilworth, UK - 4 May 2009 - Innovative pharmaceutical company…
4 May 2009/by circlek

Karus announces second closing of investment

Chilworth, UK - 6 April 2009 - Innovative pharmaceutical company…
6 April 2009/by circlek

Karus Therapeutics secures investment

Southampton, UK - 7 January 2009 - Innovative pharmaceutical…
7 January 2009/by circlek

Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.

Progress in the design and development of phosphoinositide 3-kinase…
1 January 2009/by circlek

Karus CSO presents at major industry conference

Southampton, UK - 20 October 2008 - Innovative pharmaceutical…
20 October 2008/by circlek

Karus CEO talks to Pharma TV

Karus CEO talks to Pharma TV
1 July 2008/by circlek

Ann Hacker joins Karus board

Southampton, UK - 2 April 2008 - Innovative pharmaceutical company…
2 April 2008/by circlek

Karus appoints Stephen Shuttleworth as Chief Scientific Officer

Southampton, UK - 1 January 2008 - Innovative pharmaceutical…
1 January 2008/by circlek

Karus Scientist presents at key industry conferences

Southampton, UK - 23 October 2007 - Innovative pharmaceutical…
23 October 2007/by circlek

Karus signs co-development agreement with EOS

Southampton, UK - 1 October 2007 - Innovative pharmaceutical…
1 October 2007/by circlek

Karus raises £0.82 million investment

Southampton, UK - 1 July 2007 - Innovative pharmaceutical company…
1 July 2007/by circlek

Drummond Paris named as Chairman of Karus Therapeutics

Southampton, UK - 12 October 2006 - Innovative biopharmaceutical…
12 October 2006/by circlek

Karus Therapeutics appoints Simon Kerry as CEO

Southampton, UK - 2 May 2006 - Karus Therapeutics, an emerging…
2 May 2006/by circlek

Collaboration with Sareum Holdings

Southampton, UK - 13 December 2005 - Karus Therapeutics is pleased…
13 December 2005/by circlek

Cancer and heart disease drug discovery company is latest spin-out from Southampton University

Southampton, UK - 21 July 2005 - A new spin-out company from…
21 July 2005/by circlek